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a b s t r a c t
            
Sipuleucel-T, the ﬁrst autologous cellular immunotherapy approved by the United States Food and Drug
Administration, is designed to stimulate an immune response to prostate cancer. Sipuleucel-T is man-
ufactured by culturing a patient’s peripheral blood mononuclear cells, including autologous antigen
presenting cells (APCs), with a recombinant protein comprising a tumor-associated antigen (prostatic
acid phosphatase [PAP]) and granulocyte colony-macrophage stimulating factor (GM-CSF). A full course
of treatment comprises 3 infusions of sipuleucel-T, given at approximately 2-week intervals. The pat-
tern of APC activation is consistent with priming by the ﬁrst infusion, and boosting by the second and
third infusions. Preclinical and clinical studies have demonstrated evidence of a robust antigen-speciﬁc
immune response that includes a progressive and persistent increase in antigen-speciﬁc cellular and
humoral immune responses. Treatment with sipuleucel-T has demonstrated a survival beneﬁt in Phasemmunotherapy 3 studies of subjects with metastatic castrate resistant (hormone refractory) prostate cancer (mCRPC).
Adverse events with sipuleucel-T were generally mild to moderate and resolved within 2 days. Serious
adverse events, autoimmune events, and cerebrovascular events occurred at a similar rate to control sub-
jects. As the ﬁrst autologous cellular immunotherapy to demonstrate an improvement in overall survival
in asymptomatic or minimally symptomatic mCRPC patients, sipuleucel-T represents a new treatment
paradigm in oncology.. Introduction
Prostate cancer is the second leading cause of death from cancer
mong males in most western countries, and is estimated to result
n over 33,000 deaths in the United States in 2011 [1]. The choice
f initial therapy for prostate cancer will, in part, be dependent on
atient age, cancer growth rate, and other prognostic factors. In
atients with localized cancer, and in whom active surveillance is
ot an option, surgery or radiation therapy can cure the majority
f these patients; however, up to 30% of patients will experience
isease recurrence, which is often identiﬁed by a progressive rise
n serum prostate speciﬁc antigen (PSA). Despite initial control of
isease recurrence with hormone therapy (androgen-deprivation
herapy), the disease inevitably progresses to metastatic castrate-
esistant prostate cancer (mCRPC).
Patients with mCRPC have traditionally been treated with
hemotherapeutic agents (docetaxel) or secondary hormone ther-
py and, eventually, palliative care. The concept of utilizing
umor-speciﬁc immune-based therapies to promote an adaptive
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anti-tumor response has been suggested as a potentially less
toxic and effective treatment option in these patients. While a
variety of approaches have led to immune responses to tumor
antigens, demonstration of survival beneﬁt has remained elu-
sive until recently. In 2010, sipuleucel-T, an autologous cellular
immunotherapy, was approved by the United States Food andDrug
Administration based on a demonstrated survival beneﬁt in men
with asymptomatic or minimally symptomatic mCRPC.
Sipuleucel-T is designed to stimulate an anti-tumor immune
response. It is prepared from autologous antigen presenting
cells (APCs) that are incubated with a recombinant pro-
tein composed of prostatic acid phosphatase (PAP) linked to
granulocyte-macrophage colony-stimulating factor (GM-CSF). PAP
was identiﬁed as an attractive antigen target because it is expressed
in prostatic tissue and the vast majority of prostate carcinomas,
exhibitsminimal or no expression in other tissues [2], and does not
share a high degree of sequence homology with any other known
protein. The GM-CSF moiety enhances antigen uptake by APCs.2. Preclinical development of sipuleucel-T
In preclinical development, 3 treatments (at 14-day intervals) of
APCs incubatedwith a recombinant fusion protein consisting of rat
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These events generally occurred within 1 day of infusion, were mild
or moderate in severity, and resolved within 2 days. There was
no evidence of an increased incidence of autoimmune events or
Table 1
Treatment effect of sipuleucel-T on overall survival [6,7].
D9901/D9902A D9902B (IMPACT)
Randomized (N) 225 512
Sipuleucel-T (N) 147 341ig. 1. (A) Histological staining of prostate tissue from control rats immunized APCs
rchitecture of the prostate. (B) Histological staining of prostate tissue from rats im
AP and rat GM-CSF elicited lymphocytic inﬁltrates in rat prostate
issue [3] (Fig. 1B).
The  high tissue speciﬁcity of the treatment, with immune cell
nﬁltration seen only in prostate tissue, indicated the breaking
f tolerance to a self-antigen, and the effective engagement of
he adaptive arm of the immune system. Of note, the treatment
esponse was attenuated when either APCs or GM-CSF (Fig. 1A)
ere removed from the preparation, suggesting that all 3 treat-
ent components (APCs, GM-CSF, and target antigen) were critical
or producing a robust T cell response. Additional preclinical experi-
ents demonstrated that when PAP-expressing tumor cells (MatLu
ells) were co-cultured with splenocytes from animals immunized
ith PAP-GM-CSF pulsed APCs, tumor cell proliferation was inhib-
ted [3].
.  Clinical development of sipuleucel-T
In clinical development, sipuleucel-T was manufactured from
utologous APC-containing peripheral blood mononuclear cells
PBMCs) of prostate cancer patients. PBMCs were obtained from
 leukapheresis procedure that processes 1.5–2.0 times the blood
olume of the subject. These cells were cultured for 36–44 h with
A2024, the recombinant fusion protein of human PAP-GM-CSF,
rior to reinfusion. Of note, sipuleucel-T comprises multiple types
f mononuclear cells including APCs, CD4 and CD8 T cells, NK cells,
nd B cells.
.1.  Efﬁcacy and safety of sipuleucel-T
Initial clinical studies demonstrated antigen-speciﬁc immune
esponses to the immunizing antigen, with no dose-limiting tox-
cities [4,5]. In the randomized, controlled, Phase 3 trials of
ipuleucel-T (D9901, D9902A, and D9902B [IMPACT]), sipuleucel-
 was manufactured from PBMCs isolated during 3 leukapheresis
rocedures at 2-week intervals (weeks 0, 2, and 4) [6–8]. The
edian values for white blood cells, and absolute neutrophil, lym-
hocyte, and monocyte counts at weeks 6, 14, and 26 remained
ithin normal ranges [9]. Control subjects received non-activated
utologous cells; i.e., cells that were maintained in the absence ofd with only PAP (in the absence of GM-CSF) were indistinguishable from the normal
ed a total of three times at two-week intervals with PAP + GM-CSF pulsed APCs.
PA2024. In the largest Phase 3 trial (IMPACT; N = 512), eligibility cri-
teria included asymptomatic or minimally symptomatic mCRPC,
and castrate level of testosterone (<50 ng/dL) achieved via medi-
cal or surgical castration [7]. Baseline demographic characteristics
demonstrated similar prognostic features in both arms.
The  results of the IMPACT trial demonstrated an overall sur-
vival beneﬁt with a 22% reduction in the risk of death, and a 4.1
month median survival beneﬁt. These results are consistent with
the results of prior Phase 3 trials (Table 1), which demonstrated a
33% reduction in risk of death and a 4.3 month median survival ben-
eﬁt. This survival prolongation is clinically meaningful in a patient
population with a median survival of less than 2 years [6,7]. A posi-
tive treatment effect was  observed in a large number of subgroups,
including those deﬁned by age, race, ECOG performance status,
number of bone metastases, and previous chemotherapy use [10].
The time to objective disease progression did not differ signiﬁcantly
between the two treatment groups in these Phase 3 studies [6,7].
Adverse events associated with sipuleucel-T were generally
infusion-related and self-limited. An integrated safety analysis
of 4 randomized, double-blind, controlled Phase 3 trials (D9901,
D9902A, IMPACT, and a randomized trial in androgen depen-
dent prostate cancer patients; n = 601 sipuleucel-T; n = 303 control)
demonstrated that the adverse events that were more commonly
observed with sipuleucel-T (at a rate at least twice that of control)
were: chills (53.1%), pyrexia (31.3%), headache (18.1%), myalgia
(11.8%), inﬂuenza-like illness (9.7%), and hyperhidrosis (5.0%) [11].Control (N) 78  171
Hazard ratio 0.666  0.778
95% CI 0.487, 0.912 0.614, 0.979
P-value 0.011 0.032
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econdary malignancies. The incidence of reported serious adverse
vents was 24.0% for sipuleucel-T and 25.1% for control subjects.
rade ≥3 adverse events were reported within 1 day of infusion for
.7% of sipuleucel-T and 2.3% of control subjects. The cerebrovascu-
ar event incidence rate reported was 3.5% for sipuleucel-T subjects
nd 2.6% for control subjects, and there was no evidence of a dif-
erence in the time to onset of cerebrovascular events (293 days
range: 2–1328] vs. 301.5 days [range: 7–707] for sipuleucel-T vs.
ontrol, respectively), or in the incidence of non-neurologic arte-
ial (1.0% vs. 0.7%; sipuleucel-T vs. control) or venous (2.8% vs. 4.0%)
ascular events [11].
.2.  Immunological parameters associated with sipuleucel-T
Product characterization from the IMPACT trial demonstrated
hat APC activation (assessed via CD54 upregulation [12]) was evi-
ent in all products, and the magnitude of activation was greater
n the second and third products; APC activation was not observed
n the control product [13]. The magnitude of cumulative CD54 up-
egulation in these 3 trials correlated with overall survival [14]. A
imilar pattern of increased product activation in the second and
hird products, compared with ﬁrst product, was observed with
espect to APC activation-associated cytokines (IL-1, IL-1, IL-
2p70, and TNF) and T cell activation-associated cytokines (IL-2,
L-4, IL-5, IL-10, IL-17, IFN, and TNF) [15,16]. Furthermore, pre-
ulture cells from the second and third products demonstrated
 progressively increased antigen-speciﬁc T cell proliferation and
emory response (interferon gamma  enzyme-linked immunospot
IFN ELISPOT]) [17]. This pattern of activation is consistent with
he concept that the ﬁrst infusion primes the immune system
nd subsequent infusions boost the response. Of note, CD54 up-
egulation and enhanced T cell-associated cytokine responses were
ot observed when aliquots of pre-culture cells were incubated
ith GM-CSF in the absence of PA2024 [18], indicating the GM-
SF is not solely responsible for the observed response following
ncubation with PA2024.
Longer-term  measures of immune function obtained in a subset
f subjects in the Phase 3 IMPACT trial (6, 14, and 26 weeks after
he start of treatment) demonstrated that sipuleucel-T generates
 robust immune response. A positive antibody response at any
ost-baseline time point (antibody titer >400 by ELISA) to PA2024
as observed in 66.2% of subjects treated with sipuleucel-T (vs.
.9% of control patients), and a positive antibody response to PAP
as observed in 28.5% of subjects treated with sipuleucel-T (vs.
.4% of control subjects) [7]. Overall survival was signiﬁcantly cor-
elated with a positive antibody response to PA2024 (P < 0.001),
nd the data suggested an association between overall survival
nd a positive antibody response to PAP (P = 0.08; [7]). Signiﬁ-
ant increases in T cell proliferative responses and antigen-speciﬁc
PA2024) (IFN ELISPOT) responses were observed 2 weeks after
he ﬁnal sipuleucel-T infusion [7,13]. Thus, both product param-
ters and longer-term measures demonstrated that sipuleucel-T
reatment produces a robust immune response that includes a pro-
ressive and persistent increase in antigen-speciﬁc cellular and
umoral immune responses.
.  Conclusion
Treatment with sipuleucel-T improves overall survival in sub-
ects with asymptomatic or minimally symptomatic mCRPC;
dverse events are generally mild-to-moderate and of short dura-
ion. The pattern of activation with sipuleucel-T is consistent
ith a mechanism of priming by the ﬁrst infusion and boosting
y the second and third infusions, which results in long-lasting
ntigen-speciﬁc cellular and humoral immune responses to the
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recombinant fusion protein (PA2024) and, to a lesser extent, the
self-antigen PAP. Evidence from other active immunotherapies
suggests that the initial immune response to the targeted anti-
gen may  subsequently evolve to include additional tumor antigens
[19–22]. In sipuleucel-T trials, both APC activation and humoral
responses have been shown to correlate with overall survival [7,14].
It is believed that the treatment-induced immune response pro-
longs survival by slowing the tumor growth rate in patients with
mCRPC [19,21]. Sipuleucel-T is the ﬁrst approved autologous cel-
lular immunotherapy to demonstrate an improvement in overall
survival; it represents a new treatment paradigm in oncology.
Acknowledgements
The  author wishes to thank the patients and their families, the
participating study sites, the clinical investigators, and the contri-
butions of current and former Dendreon personnel in the conduct
of these clinical studies. Brandon Walsh, PhD, provided writing
assistance in the preparation of this manuscript.
References
[1] Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of
eliminating socioeconomic and racial disparities on premature cancer deaths.
CA Cancer J Clin 2011 June.
[2] Graddis TJ, McMahan CJ, Tamman J, Page KJ, Trager JB. Prostatic acid phas-
phatase expression in human tissues. Int J Clin Exp Pathol 2011;4(3):295–306.
[3] Laus R, Yang DM,  Ruegg CL, Shapero MH,  Slagle PH, Small EJ, et al. Dendritic
cell immunotherapy of prostate cancer: preclinical models and early clinical
experience. Cancer Res Ther Control 2001;11:1–10.
[4] Burch PA, Breen JK, Buckner JC, Gastineau DA, Kaur JA, Laus RL, et al. Priming
tissue-speciﬁc cellular immunity in a phase I trial of autologous dendritic cells
for prostate cancer. Clin Cancer Res 2000;6(June (6)):2175–82.
[5] Small EJ, Fratesi P, Reese DM,  Strang G, Laus R, Peshwa MV,  et al. Immunother-
apy of hormone-refractory prostate cancer with antigen-loaded dendritic cells.
J  Clin Oncol 2000;18(December (23)):3894–903.
[6]  Higano CS, Schellhammer PF, Small EJ, Burch PA, Nemunaitis J, Yuh L, et al.
Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3
trials of active cellular immunotherapy with sipuleucel-T in advanced prostate
cancer. Cancer 2009;115(August (16)):3670–9.
[7]  Kantoff PW,  Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al.
Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl
J  Med  2010;363(5):411–22.
[8] Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH,
et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-
T (APC8015) in patients with metastatic, asymptomatic hormone refractory
prostate cancer. J Clin Oncol 2006;24(July (19)):3089–94.
[9]  Flanigan R, Price T, Whitmore J, Holman J. Safety of leukapheresis in prostate
cancer patients receiving sipuleucel-T. J Urol 2011;185(4 (Suppl. 1)):e261
[abstract 646].
10] Hiagno CS, Small EJ, Schellhammer PF, Kantoff PW,  Redfern CH,  Nemunaitis JJ,
et al. Predictors of outcome and subgroup results from the integrated analysis
of sipuleucel-T trials in metastatic castration-resistant prostate cancer. J Clin
Oncol 2010;28(15s) [abstract 4550].
11]  Hall SJ, Klotz L, Pantuck AJ, George DJ, Whitmore JB, Frohlich MW,  et al.
Integrated safety data from 4 randomized, double-blind, controlled trials of
autologous cellular immunotherapy with sipuleucel-T in patients with prostate
cancer. J Urol 2011;186(3):877–81.
12] Sheikh NA, Jones LA. CD54 is a surrogate marker of antigen presenting cell
activation. Cancer Immunol Immunother 2008;57(September (9)):1381–90.
13] Sheikh NA, Dela Rosa C, Kuan L-Y, Stewart FP, Frohlich MW,  Urdal DL, et al.
Sipuleucel-T generates robust and persistent cellular and humoral immune
responses – results from the IMPACT trial [abstract]. Washington, DC: AACR;
2010 [abstract 2932].
14] Stewart FP, Dela Rosa C, Sheikh NA, McNeel DG, Frohlich MW,  Urdal DL, et al.
Correlation between product parameters and overall survival in three trials of
sipuleucel-T, an autologous active cellular immunotherapy for the treatment
of prostate cancer. J Clin Oncol 2010;28(15s) [abstract 4552].
15] Sheikh NA, Dela Rosa C, Frohlich MW,  Urdal DL, Provost NM. Sipuleucel-T treat-
ment results in sequential ex vivo activation of APCs and T cells during the
culture step – evidence for in vivo immunological priming [abstract]. Wash-
ington, DC: AACR; 2010 [abstract 5608].
16]  Wesley JD, Chadwick E, Kuan L-Y, Dela Rosa C, Frohlich M,  Urdal D, et al. Charac-
terization of antigen speciﬁc T cell activation and cytokine expression induced
by sipuleucel-T. J Immunother 2010;33(8):912–3.
17] Butterﬁeld LH, Disis ML,  Khleif SN, Balwit JM,  Marincola FM.  Immuno-oncology
biomarkers 2010 and beyond: perspectives from the iSBTc/SITC biomarker task
force. J Trans Med  2010;8:130.
e 30 (2
[
[
[
[21] Madan RA, Gulley JL, Fojo T, Dahut WL.  Therapeutic cancer vaccines in prostate
cancer: the paradox of improved survival without changes in time to progres-
sion. Oncologist 2010;15(9):969–75.
[22] Tuma RS. Immunotherapies in clinical trials: do they demand different evalu-R.B. Sims / Vaccin
18]  Sheikh NA, Wesley JD, Chadwick E, Perdue N, Dela Rosa C, Frohlich MW,  et al.
Characterization of antigen specifric T-cell activation and cytokine expression
induced by sipuleucel-T. J Clin Oncol 2011;29(Suppl. 7) [abstract 155].
19] Gulley JL, Drake CG. Immunotherapy for prostate cancer: recent advances,
lessons learned, and areas for further research. Clin Cancer Res 2011;17(June
(12)):3884–91.
20] Kudo-Saito C, Schlom J, Hodge JW.  Induction of an antigen cascade by diver-
siﬁed subcutaneous/intratumoral vaccination is associated with antitumor
responses. Clin Cancer Res 2005;11(6):2416–26.012) 4394– 4397 4397ation tools? J Natl Cancer Inst 2011;103(10):780–1.
